SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Greene who wrote (1440)12/30/1998 11:43:00 AM
From: tommysdad  Read Replies (1) of 2135
 
As soon as someone announces the discovery of the putative receptors, the answer will be clear (and you may want to invest in the company that does). Until then, it's kind of up in the air. Lots of biotechs and big pharmas already have anti-angiogenesis programs or compounds which are anti-angiogenic (AGPH, SUGN, etc.) which are in advanced clincial trials. None of these compounds do everything attributed to AS/ES. It is unlikely that any single small molecule will ever do everything the proteins do (why are Epogen and Neupogen still billion dollar drugs?), but that may not matter. Ten or fifteen different drugs that cover the spectrum would be just as detrimental to the ENMD's future.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News